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multi-dose oral ondansetron for pediatric
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Christopher McCabe7, Gareth Hopkin7, Amy C. Plint8,9,10, Andrew Dixon11, Darcy Beer12, Serge Gouin13,14,
Gary Joubert15, Terry P. Klassen16,17, Stephen B. Freedman18 and on behalf of the PERC-KIDSCAN DOSE-AGE Study
Group
Abstract
Background: Acute gastroenteritis is a leading cause of emergency department visits and hospitalizations among
children in North America. Oral-rehydration therapy is recommended for children with mild-to-moderate
dehydration, but children who present with vomiting are frequently offered intravenous rehydration in the
emergency department (ED). Recent studies have demonstrated that the anti-emetic ondansetron can reduce
vomiting, intravenous rehydration, and hospitalization when administered in the ED to children with dehydration.
However, there is little evidence of additional benefit from prescribing ondansetron beyond the initial ED dose.
Moreover, repeat dosing may increase the frequency of diarrhea. Despite the lack of evidence and potential adverse
side effects, many physicians across North America provide multiple doses of ondansetron to be taken following ED
disposition. Thus, the Multi-Dose Oral Ondansetron for Pediatric Gastroenteritis (DOSE-AGE) trial will evaluate the
effectiveness of prescribing multiple doses of ondansetron to treat acute gastroenteritis-associated vomiting. This
article specifies the statistical analysis plan (SAP) for the DOSE-AGE trial and was submitted before the outcomes of
the study were available for analysis.
Methods/design: The DOSE-AGE study is a phase III, 6-center, placebo-controlled, double-blind, parallel design
randomized controlled trial designed to determine whether participants who are prescribed multiple doses of oral
ondansetron to administer, as needed, following their ED visit have a lower incidence of experiencing moderate-to-
severe gastroenteritis, as measured by the Modified Vesikari Scale score, compared with a placebo. To assess safety,
the DOSE-AGE trial will investigate the frequency and maximum number of diarrheal episodes following ED
disposition, and the occurrence of palpitations, pre-syncope/syncope, chest pain, arrhythmias, and serious adverse
events. For the secondary outcomes, the DOSE-AGE trial will investigate the individual elements of the Modified
Vesikari Scale score and caregiver satisfaction with the therapy.
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Discussion: The DOSE-AGE trial will provide evidence on the effectiveness of multiple doses of oral ondansetron,
taken as needed, following an initial ED dose in children with acute gastroenteritis-associated vomiting. The data
from the DOSE-AGE trial will be analyzed using this SAP. This will reduce the risk of producing data-driven results
and bias in our reported outcomes. The DOSE-AGE study was registered on ClinicalTrials.gov on February 22, 2019.
Trial registration: ClinicalTrials.gov NCT03851835. Registered on 22 February 2019.
Keywords: Acute gastroenteritis, Emergency department, Pediatrics, Ondansetron, Statistical analysis plan
Background
In the USA, nearly 50 million episodes of acute gastro-
enteritis occur each year [1]. In addition, nearly 2 million
infected children are brought for emergency department
(ED) care each year [2]. Rehydration is the cornerstone
of care for minimally dehydrated children with acute
gastroenteritis. They are encouraged to consume their
preferred solutions [3] with electrolyte maintenance so-
lution being recommended for those with some dehydra-
tion [4]. For children who experience vomiting, the
antiemetic agent ondansetron is used to facilitate rehy-
dration [5], with around 87% of pediatric ED physicians
using antiemetics in these settings [6].
A 2016 meta-analysis identified that a single dose of
oral ondansetron reduces the use of intravenous rehy-
dration and hospital admissions, compared to placebo,
in children who present for ED care with gastroenteritis-
associated vomiting [7]. However, no evidence currently
exists to indicate that additional doses of oral ondanse-
tron taken at home lead to improved outcomes; some
evidence even suggests an increase in adverse events
(AE) [8]. Despite the lack of studies evaluating at-home
oral ondansetron administration, it is commonly pre-
scribed at discharge in many EDs across North America
[9]. Thus, we designed the DOSE-AGE study to evaluate
the effectiveness and safety of multiple doses of ondan-
setron provided to children with acute gastroenteritis-
associated vomiting, following an initial ED dose.
The DOSE-AGE study is a phase 3 study that will
investigate the effect of prescribing multiple doses of
oral ondansetron, administered at home, on the prob-
ability of experiencing moderate-to-severe gastroenter-
itis in the 7 days following trial enrollment, compared
to placebo. The study will enroll children and youth
who present to any of six participating EDs with
acute gastroenteritis-associated vomiting who are pre-
scribed an initial dose in the ED. The study protocol
is available [10] and this article outlines the statistical
analysis plan (SAP) for the DOSE-AGE study. The
analyses identified in this SAP will be included in fu-
ture study abstracts and manuscripts. This SAP has
been published before completing the data collection
for the DOSE-AGE study and aims to reduce the po-
tential for bias in the final trial report.
Objectives
The primary aim of the DOSE-AGE study is to deter-
mine if the provision of a 6-dose (i.e., 2 days) supply of
oral ondansetron prior to ED discharge will result in a
reduction in the proportion of children who experience
moderate-to-severe gastroenteritis symptoms, quantified
by the Modified Vesikari Scale (MVS) score [11, 12], fol-
lowing discharge, compared to the placebo. We will en-
roll children and youth 6 months to 18 years of age, who
were previously healthy, and present to one of six Can-
adian participating pediatric EDs with gastroenteritis-
associated vomiting. The secondary objectives of the
DOSE-AGE study are to investigate the effect of multi-
dose oral ondansetron on possible adverse events (e.g.,
diarrhea), caregiver satisfaction, intravenous rehydration,
and unscheduled health care provider visits.
Methods/design
Design and setting
The DOSE-AGE trial is a phase 3, placebo-controlled,
double-blind, parallel design randomized controlled trial
being conducted in 6 Canadian tertiary care pediatric
EDs. All eligible participants will be administered a dose
of ondansetron in the ED as part of their routine clinical
care. The active treatment, to be compared with a pla-
cebo control, will be an at-home kit that contains 6
ondansetron elixir treatment doses plus 2 extra in case
of spillage or vomiting, dosed at 0.15 mg/kg to a max-
imum single dose of 8 mg, to be administered at least 8
h after the initial clinical dose in the ED. Over the fol-
lowing 48 h, the intervention will be administered, at the
discretion of the participant or caregiver, every 8 h with
a maximum of 3 doses in a 24-h period. This “active” at-
home treatment will be contrasted with the “placebo”
treatment by randomizing participants in a 1:1 ratio to
either the active or placebo treatment. All study
personnel including data analysts will be blinded to the
study group assignment. Participants will be followed up
for 7 days after randomization with questionnaires issued
24 h, 48 h, and 7 days (i.e., 168 h) post-enrollment.
Study protocol development and conduct
The DOSE-AGE study was registered on ClinicalTrials.-
gov on February 22, 2019 with the trial registration
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number NCT03851835. Research Ethics Board (REB) at
each participating institution approved the study prior to
commencing local enrollment. Informed consent will be
obtained from caregivers and mature minors, as defined
by local regulations, before randomization, data collec-
tion, or the performance of any study procedures. Assent
will be obtained based on the child’s age, as appropriate.
All consent and assent procedures will follow institu-
tional REB guidelines. The DOSE-AGE study is part of
the KidsCAN-PERC iPCT network [13]. This Canadian
trials network is undertaking four trials using a central-
ized infrastructure for data management and trial over-
sight. Within this network, an independent data and
safety monitoring board (DSMB) has been recruited to
oversee the DOSE-AGE study.
Randomization and data collection
Participants eligible for the DOSE-AGE study will be
randomized in a 1:1 allocation ratio using a permuted
block randomization procedure with various block sizes.
We will stratify participants by clinical site and partici-
pant weight, < 20 kg and ≥ 20 kg, to ensure that site or
weight-specific variations are distributed across
treatment arms. We use weight, as opposed to age, to
stratify participants as dosing is weight-based.
Randomization will be undertaken using an Internet-
based randomization service (www.randomize.net) to
provide randomization kit numbers. A secure list will be
sent to each site pharmacy where pharmacy staff will
prepare consecutively numbered study kits according to
the randomization schedule. The kits will then be
grouped, and the assigned kit will be chosen at random
within that group at the point of participant
randomization.
All study participants data will be stored at the data
coordination center (DCC) located at the Women and
Children’s Health Research Institute (WCHRI) at the
University of Alberta [14]. Data for analysis will be en-
tered and stored in the REDCap electronic data capture
system [15]. During the data collection process, some
data may be recorded on paper and transcribed into the
database or obtained from the participants and entered
directly into the database. This electronic system will be
based at the DCC and housed in a secure data center at
the University of Alberta Hospital. Prior to analysis, all
identifying information (e.g. contact information) will be
removed and individual participants will be identified
with a unique study identification number.
Primary outcome
The primary outcome is the development of moderate-
to-severe gastroenteritis in the 7 days following presen-
tation to an ED. Moderate-to-severe gastroenteritis is
defined as an MVS score in the 7 days post-
randomization greater than or equal to 9 [12]. The MVS
is a composite measure that includes seven components
that are each assigned a score based on data collected
between randomization and the completion of day 7
follow-up. The components will be calculated based on:
1. The duration of diarrhea following randomization,
measured in hours.
2. The maximal number of episodes of diarrhea in any
given 24-h period post-randomization.
3. The duration of vomiting following randomization,
measured in hours.
4. The maximal number of episodes of vomiting in
any given 24-h period post-randomization.
5. The maximal participant temperature recorded
post-randomization.
6. The presence and type of unscheduled visits to a
healthcare provider. If the participant records an
ED visit to a participating site, this will be verified
by database/chart review.
7. The type of treatment, if any, received for
gastroenteritis in the 7 days post-randomization.
The scoring procedure for the MVS based on this in-
formation is given in Table 1.
Secondary efficacy outcomes
The DOSE-AGE study will include six secondary out-
comes to investigate the efficacy of multiple dose ondan-
setron compared to placebo.
1. The total number of episodes of vomiting across
the 7 days post-randomization.
2. The time interval from randomization until the
participant ceases vomiting. A participant with a
24-h period without either vomiting or diarrhea will
be assumed to have ceased vomiting.
3. The proportion of participants who experience
vomiting within 7 days of enrollment.
4. The proportion of participants who have an
unscheduled health care provider visit within 7 days
of enrollment.
5. The proportion of participants who receive
intravenous rehydration within 7 days of
enrollment.
6. Caregiver satisfaction with the treatment provided
in the 48 h following ED disposition, as measured
by a 5-point Likert scale.
Safety outcomes
To investigate the safety of multiple doses of ondanse-
tron, we will record the total number of diarrheal epi-
sodes during the 48-h following randomization, the
maximal number of diarrheal episodes in a 24-h period
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during the 7 days following randomization, and the
number of participants who experience any serious ad-
verse events (SAEs), palpitations, pre-syncope/syncope,
chest pain, and arrhythmias.
Sample size calculation
The primary outcome in the DOSE-AGE trial is binary,
the development of moderate-to-severe gastroenteritis in
7 days following randomization. Pilot data indicate that
30% of participants will have moderate-to-severe disease
following the index visit [17, 18]. A survey of experts in-
dicated that an absolute risk reduction of 10% would
constitute a minimal clinically important difference
(MCID) [19]. Therefore, our sample size calculation as-
sumed a 30% event rate in the control group for which
we desire to detect an absolute beneficial treatment ef-
fect of 10% with 90% power. Using a two-sided type I
error of 0.05, the total sample size for the DOSE-AGE
trial is 784 participants. We assumed a 10% loss to
follow-up ð7840:9 ¼ 870Þ, 5% drop out, and 3% drop in rate
(i.e., caregivers who are provided with ondansetron
outside the study protocol) ð 870
0:922
¼ 1030Þ. Thus, the total
number randomized will be 1030. As a sensitivity ana-
lysis, we have computed the power for the DOSE-AGE
trial based on potential alternative event rates for the ac-
tive treatment and placebo groups (Table 2).
Interim analysis and stopping guidance
There are no planned interim analyses for the primary or
secondary outcomes and early stopping for efficacy or futil-
ity will not be considered due to concerns about over- or
under-estimating effects [20, 21]. The DSMB will consider
stopping for safety. Statisticians tasked with providing the
interim analyses to the DSMB will be blinded to the iden-
tity of the treatment arms, and DSMB reports will use
treatments “A” and “B” throughout the reporting. The
DSMB can be unblinded to treatment arm if required.
Statistical analysis plan
Statistical principals
Outcomes will be collected using follow-up surveys pro-
vided to caregivers 24 h, 48 h, and 168 h after
Table 1 Modified Vesikari Scale scoring table. The scoring table to compute the Modified Vesikari Scale score from the survey
outcomes in the DOSE-AGE trial
Scale component Score on the Vesikari Scale
0 points 1 point 2 points 3 points
Duration of diarrhea symptoms (hrs) 0 < 96.0 96.0 to < 120 ≥ 120
Maximum no. of watery stools in 24 h, across the 7-day follow-up 0 1–3 4–5 ≥ 6
Duration of vomiting (hrs) 0 < 24.0 24.0 to < 48.0 ≥ 48.0
Maximum no. of vomiting episodes in 24 h, across the 7-day follow-up 0 1 2–4 ≥ 5
Maximum recorded rectal temperature (corrected) (°C) < 37.0 37.0 to < 38.5 38.5 to < 39.0 ≥ 39.0
Unscheduled health care visit 0 NA Primary care Emergency
department
Treatment None Rehydration with
intravenous fluids
Hospitalization NA
Temperatures will be adjusted for the location of measurement: 1.1 °C will be added to axillary temperatures and 0.6 °C will be added to oral temperatures [16]
hrs hours, No. number, IV intravenous
Table 2 Expected power for different event rates. The statistical power of the DOSE-AGE trial with 784 participants based on
different assumptions for the true probability of moderate-to-severe gastroenteritis in 7 days following enrollment, as measured by
the Modified Vesikari Scale score




0.25 0.15 0.10 0.94
0.25 0.2 0.05 0.39
0.25 0.25 0.0 NA
0.3 0.15 0.15 0.999
0.3 0.25 0.05 0.35
0.35 0.15 0.2 ~ 1
0.35 0.2 0.15 0.997
0.35 0.25 0.1 0.87
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randomization. Following ED disposition, study staff will
contact caregivers using their preferred method of com-
munication, e-mail or telephone, to collect the out-
comes. The final analysis comparing oral ondansetron to
placebo will take place in one stage with the main results
prepared after every participant has completed the
protocol and all data have been collected and cleaned,
and the database has been locked. The analysis will be
performed blinded to participant treatment allocation.
The final trial analysis will test for the superiority of
the active treatment compared to placebo for all primary
and secondary outcomes. We will use an intention-to-
treat (ITT) principle and include all randomized partici-
pants, regardless of whether they adhered to the
protocol. The safety analysis population will be any par-
ticipants that took at least one dose of the study medica-
tion. We will declare statistical significance at the 5%
level using two-sided tests for all inferential analyses.
We will use the Bonferroni-Holm correction to maintain
the family-wise error rate at 5% for the secondary out-
comes, although we note that these analyses are explora-
tory as the trial has not been powered for these
comparisons. We will report all estimates for the treat-
ment effects using 95% confidence intervals, calculated
using SAS or R [22, 23].
Handling of missing data
Subjects who withdraw from the study or are lost to
follow-up will have all available data used in the analysis.
Data from the follow-up questionnaires, required to de-
rive the primary outcome, may be missing. In these
cases, we will use multiple imputation [24]. To minimize
the use of imputation, only missing components will be
imputed and then used to calculate variables, as re-
quired. For example, if the end date of diarrhea is miss-
ing, then this will be imputed and then used to calculate
the duration of diarrhea. We aim to impute and analyze
10 datasets but will increase that number if the efficiency
of the imputed datasets is less than 0.99 or if the propor-
tion of missing observations is greater than 10% [25]. If
greater than 10% of subjects are withdrawn or lost to
follow-up, baseline characteristics and other information
will be used to assess whether there is difference be-
tween the missing and non-missing subjects. If there is a
difference, then we will explore the impact of alternative
missing data assumptions on the results [26].
Patient flow
We will use a CONSORT 2010 flow diagram to present
patient flow for the DOSE-AGE trial. The diagram will
report the number of participants deemed eligible for
the trial at screening and those excluded as they met a
study exclusion criteria. We will detail the number of
participants who were randomized and received the ran-
domized allocation.
Participants can withdraw from the DOSE-AGE study
at any time and for any reason. The reason for voluntary
withdrawal from the study will not be collected. Partici-
pants who choose to withdraw from the study can
choose to discontinue the study intervention but
complete the follow-up questionnaires or to withdraw
from all further data collection. The site investigator
may discontinue or withdraw a participant from the
study if the participant meets an exclusion criterion that
precludes study participation or if any clinical adverse
event or other medical condition occurs such that study
participation is not in the best interest of the patient.
Reasons for withdrawal (i.e., caregiver- or investigator-
initiated) and the number of participants lost to follow-
up will be summarized by treatment arm.
Protocol deviations
A minimum level of study doses (i.e., compliance) will
not be required for this trial as it is not mandatory for
caregivers to provide the study intervention to the par-
ticipant. Thus, no deviation will be recorded if a care-
giver does not administer the study intervention.
Descriptive statistics on the number of doses provided
will be presented by treatment group. Protocol violations
are defined in keeping with ICH GCP guidelines.
The number and percentage of participants with
protocol violations will be summarized by treatment
group with details of the violation provided. Participants
included in the ITT analysis data set will be used as the
denominator to calculate protocol violation percentages.
No formal testing will be undertaken.
Baseline characteristics
All trial participants will be described in terms of age,
sex, weight, whether they attend day care or school, and
whether they have access to a primary care physician.
Initial gastroenteritis severity will be recorded using
vomiting and diarrhea duration and maximal 24-h fre-
quency before attending the ED, the presence and height
of fever, prior ED visits for the current illness, IV rehy-
dration, hospitalization, baseline MVS, antibiotic usage
in the preceding 14 days, dehydration assessment, and
the need for hospitalization at the initial ED visit.
Our presentation of these baseline characteristics will
depend on the type of data. In particular, categorical var-
iables will be compared between the active and placebo
groups using frequency counts and percentages. All con-
tinuous variables will be presented using the mean, me-
dian, standard deviation, and interquartile range.
Baseline characteristics will not be subject to formal stat-
istical testing.
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Analysis for the primary endpoint
The primary outcome, occurrence of moderate-to-severe
gastroenteritis, will be compared across treatment
groups using the logistic mixed model, adjusted for site
and weight category. We will provide summary statistics
of the effect size by reporting the absolute risk differ-
ence, relative risk, and odds ratios across the two treat-
ment groups, alongside 95% confidence intervals.
Confidence intervals will be obtained using the profile
likelihood method with identity, log, and logit link func-
tions, respectively, in a generalized linear mixed model
[27]. If any participants are randomized within an incor-
rect stratum due to misspecification at time of
randomization, the actual rather than assigned category
will be used in the primary analysis.
Analysis for secondary endpoints
Secondary outcomes
Secondary outcome 1 records the number of episodes of
vomiting within the 7-day study follow-up. This will be
compared across treatment groups using a generalized
linear model to compare differences between Poisson
rates while adjusting for stratification by site and weight.
Secondary outcome 2 will assess differences in the dur-
ation of vomiting using the Van Elteren test, stratified by
site and weight. If greater than 10% of participants still
experience symptoms at the 7-day follow-up question-
naire, we will use a suitable procedure to take account of
censoring.
Secondary outcomes 3–5 are binary and will be com-
pared across treatment groups using logistic mixed
models, stratified by site and weight. We will report the
appropriate summary statistics for all these analyses with
the corresponding adjusted 95% confidence intervals. Fi-
nally, we will test for differences in caregiver satisfaction
(secondary outcome 6) using a Mann-Whitney U test.
Safety outcomes
We will undertake formal statistical testing for the fre-
quency and maximum number of diarrhea episodes dur-
ing the 7-day follow-up period. To test for differences in
the frequency, we will use a generalized linear model to
compare differences between Poisson rates while adjust-
ing for stratification. We will then use a Mann-Whitney
U test to determine whether there are differences in the
maximum number of diarrhea episodes in 24 h. All other
safety outcomes will be reported using frequencies.
Subgroup analyses
We will consider four pre-specified subgroup analyses of
the primary outcome based on:
1. Sex
2. Age—6 months to < 3.0 years, 3.0 to < 6.0 years, 6.0
to < 10.0 years, and ≥ 10.0 years
3. Vomiting frequency, > 10 episodes in preceding 24
h
4. Presence of diarrhea (yes/no) in preceding 24 h
We will declare a significant subgroup effect if the
interaction between assigned treatment and the sub-
group factor is significant in the appropriate statistical
model at a significance level of 0.05/4 = 0.0125. Logistic
regression models will be used with a main effect for
treatment, a main effect for the subgroup variable of
interest, and an interaction between the subgroup vari-
able of interest and the treatment. We will also stratify
by site and weight in this subgroup analyses. A subgroup
analysis for safety outcomes will also be undertaken by
only including participants who received 3 or more
doses of the study medication to assess the impact of
multiple doses of ondansetron on diarrhea and other
safety outcomes.
Additional analyses
To estimate the individual-specific rather than the popu-
lation level effects, we will perform secondary analyses
of the MVS score outcomes by assessing the treatment
effect after adjustment for covariates, including:
 Baseline MVS (actual score)
 Duration of symptoms prior to enrollment (< 48 h




 Antibiotic usage during the 14 days prior to the ED
visit
 Severity (i.e., frequency) of baseline diarrhea and
vomiting
 Dehydration assessment
 Need for hospitalization at the index visit
We will use a logistic regression model employing the
presence of moderate-to-severe disease as the dependent
variable. We will also analyze the MVS outcome as a
continuous variable using a linear mixed model, if ap-
propriate, or a Van Elteren test, stratified by center and
weight, to compare across treatment groups.
We will additionally analyze the total number of days
that participants experience vomiting (i.e., secondary
outcome 1) using a linear regression model to adjust for
possible effects of the above covariates. We will also
undertake a Bayesian exploratory analysis for the
primary and secondary outcomes [28]. Finally, the
DOSE-AGE trial is accompanied by a discrete choice ex-
periment (DCE) aimed at examining caregiver
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preferences for the components of the MVS score. We
will use the DCE to develop a preference-weighted scor-
ing system for the MVS score. As an additional analysis,
we will undertake the primary analysis using this
preference-weighted MVS score as a continuous
variable.
Trial status
The DOSE-AGE study was registered on February 22,
2019, and started recruitment in September 2019 at the
Alberta Children’s Hospital. The final institution is ex-
pected to begin recruitment of patients by February
2020. Recruitment is currently underway and is expected
to complete around June 2022. The database will be
cleaned and checked for completeness before the data
are analyzed. At this point, the database will be locked,
and the statistical analysis will be undertaken using the
methods specified in this SAP.
Abbreviations
AGE: Acute gastroenteritis; DSMB: Data Safety and Monitoring Board;
MVS: Modified Vesikari Score; ED: Emergency department; DOSE-AGE: Multi-
DOSE Oral Ondansetron for Pediatric Acute Gastroenteritis; (S)AE: (Serious)
adverse events; CONSORT: Consolidated Standards of Reporting Trials;
IV: Intravenous; ITT: Intention-to-treat; DCC: Data coordination center;
WCHRI: Women and Children’s Health Research Institute
Acknowledgements
We thank all members of the KidsCAN PERC Innovative Pediatric Clinical
Trials DOSE-AGE Study Group and the KidsCAN PERC Innovative Pediatric
Clinical Trials Methods Core (Eleanor Pullenayegum, Jeff Round, and Andy
Willan) for assistance in developing the protocol and statistical analysis plan
for the DOSE-AGE trial. The DOSE-AGE study would also like to acknowledge
Dr. Dennis Cote, Dr. Garth Meckler, Dr. Mark Roback, Dr. Anupam Kharbanda,
Dr. Eyal Cohen, Dr. Lise Nigrovic, and Dr. Geert W. ‘t Jong. They would also
like to acknowledge the KidsCAN PERC Innovative Pediatric Clinical Trials
team and our parent advisors (Serena Hickes, Kurt Schreiner, Julie Leung)
who provided valuable input on the study design and documents. We want
to thank the Pediatric Emergency Research Canada (PERC) network of health
care professionals and the KidsCAN Trials Network for their contribution and
support to this project and pediatric clinical research in Canada.
The DOSE-AGE Study group comprises Dr. Stephen Freedman, Sarah
Williamson-Urquhart, Dr. Terry Klassen, Tannis Erickson, Rick Watts, Pam Mar-
ples, Dr. Anna Heath, David Rios, Dr. Petros Pechlivanoglou, Dr. Chris McCabe,
Dr. Gareth Hopkin, Dr. Amy Plint, Tremaine Rowe, Dr. Gary Joubert, Leslie
Boisvert, Dr. Serge Gouin, Marie-Christine Auclair, Dr. Andrew Dixon, Manasi
Rajagopal, Mithra Sivakumar, Dr. Darcy Beer, and Jeannine Schellenberg.
Authors’ contributions
AH, DR, SWU, PP, MO, CM, GH, AP, AD, DB, SG, GJ, TK, and SF were involved
in the conception and design of the SAP. AH and DR drafted the
manuscript. SWU, PP, MO, CM, GH, AP, AD, DB, SG, GJ, TK, and SF offered
substantive revisions. All authors read, edited, and approved the final
manuscript. All individuals mentioned in the “Acknowledgements” section
are members of the DOSE-AGE Study Group.
Funding
This work is funded through an Innovative Clinical Trials Multi-year Grant
from the Canadian Institutes of Health Research (funding reference number
MYG-151207; 2017–2020), as part of the Strategy for Patient-Oriented Re-
search and in partnership with the Alberta Children’s Hospital Research Insti-
tute (Calgary, Alberta), Centre Hospitalier Universitaire Sainte-Justine
(Montreal, Quebec), Children’s Hospital Research Institute of Manitoba (Winni-
peg, Manitoba), CHEO Research Institute (Ottawa, Ontario), Hospital for Sick
Children Research Institute (Toronto, Ontario), Stollery Children’s Hospital (Ed-
monton, Alberta), Research Manitoba (Winnipeg, Manitoba), University of
Western Ontario (London, Ontario), and the Women and Children’s Health
Research Institute (Edmonton, Alberta). Dr. Stephen Freedman is supported
by the Alberta Children’s Hospital Foundation Professorship in Child Health
and Wellness. The funding agreement ensured the authors’ independence in
designing the study, interpreting the data, writing, and publishing the report.
Availability of data and materials
No datasets were used to develop this article as analysis was not
undertaken. Thus, this consideration is not applicable.
Ethics approval and consent to participate
We have obtained primary ethical approval from the Conjoint Health
Research Ethics Board at the University of Calgary with reference number:





Dr. Stephen Freedman has received in-kind grant support from Novartis and
GlaxoSmithKline and is a consultant to RedHill BioPharma Ltd.
Author details
1University of Toronto, Toronto, Ontario, Canada. 2University College London,
London, United Kingdom. 3Child Health Evaluative Sciences, The Hospital for
Sick Children, Toronto, Ontario, Canada. 4Pediatric Emergency Research
Team, Alberta Children’s Hospital, University of Calgary, Calgary, Alberta,
Canada. 5Institute of Health Policy, Management and Evaluation, University of
Toronto, Toronto, Ontario, Canada. 6Division of Neonatology, The Hospital for
Sick Children, University of Toronto, Toronto, Ontario, Canada. 7Institute of
Health Economics, Edmonton, Alberta, Canada. 8Division of Emergency
Medicine, Children’s Hospital of Eastern Ontario, Ottawa, Canada. 9University
of Ottawa, Ottawa, Canada. 10Children’s Hospital Research Institute, Ottawa,
Canada. 11Stollery Children’s Hospital, University of Alberta, Women’s and
Children’s Health Research Institute, Edmonton, Canada. 12Pediatrics/Pediatric
Emergency Medicine, Department of Pediatrics and Child Health, Children’s
Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada.
13Université de Montréal, Montréal, Québec, Canada. 14CHU Sainte-Justine,
Montréal, Québec, Canada. 15Children’s Hospital, Western University, London,
Ontario, Canada. 16University of Manitoba, Winnipeg, Manitoba, Canada.
17Children’s Hospital Research Institute of Manitoba, Winnipeg, Manitoba,
Canada. 18Sections of Pediatric Emergency Medicine and Gastroenterology,
Department of Pediatrics, Alberta Children’s Hospital, Alberta Children’s
Hospital Research Institute, Cumming School of Medicine, University of
Calgary, Calgary, Alberta, Canada.
Received: 9 March 2020 Accepted: 4 August 2020
References
1. Scallan E, Griffin P, Angulo F, Tauxe R, Hoekstra R. Foodborne illness
acquired in the United States—unspecified agents. Emerg Infect Dis. 2011;
17(1):16.
2. Freedman S, Steiner M, Chan K. Oral ondansetron administration in
emergency departments to children with gastroenteritis: an economic
analysis. PLoS Med. 2010;7(10):e1000350.
3. Freedman S, Willan A, Boutis K, Schuh S. Effect of dilute apple juice and
preferred fluids vs electrolyte maintenance solution on treatment failure
among children with mild gastroenteritis: a randomized clinical trial. Jama.
2016;315(18):1966–74.
4. Bresee J, Duggan C, Glass R, King C. Managing acute gastroenteritis among
children; oral rehydration, maintenance, and nutritional therapy. MMWR.
2003;52:1–16.
5. Freedman S, Gouin S, Bhatt M, Black K, Johnson D, Guimont C, Joubert G,
Porter R, Doan Q, Van Wylick R, Schuh S. Prospective assessment of practice
pattern variations in the treatment of pediatric gastroenteritis. Pediatrics.
2011;127(2):e287–95.
6. Nunez J, Liu D, Nager A. Dehydration treatment practices among pediatrics-
trained and non–pediatrics trained emergency physicians. Pediatr Emerg
Care. 2012;28(4):322–8.
Heath et al. Trials          (2020) 21:735 Page 7 of 8
7. Tomasik E, Ziółkowska E, Kołodziej M, Szajewska H. Systematic review with
meta-analysis: ondansetron for vomiting in children with acute
gastroenteritis. Aliment Pharmacol Ther. 2016;44(5):438–46.
8. Yilmaz H, Yildizdas R, Sertdemir Y. Clinical trial: oral ondansetron for
reducing vomiting secondary to acute gastroenteritis in children–a double-
blind randomized study. Aliment Pharmacol Ther. 2010;31(1):82–91.
9. Gray J, Maewal J, Lunos S, Furnival R, Hendrickson M. Ondansetron
prescription for home use in a pediatric emergency department. Pediatr
Emerg Care. 2017;0(0):1–5.
10. Freedman S, Williamson-Urquhart S, Heath A, Pechlivanoglou P, Hopkin G,
Gouin S, Plint A, Dixon A, Beer A, JG, McCabe C, Finkelstein Y, Klassen T.
Multi-dose Oral Ondansetron for Pediatric Gastroenteritis: Study Protocol for
the multi-DOSE oral ondansetron for pediatric Acute GastroEnteritis (DOSE-
AGE) Pragmatic Randomized Controlled Trial. Trials. 2020;21(435):1–13.
11. Freedman S, Eltorky M, Gorelick M, PERC Gastroenteritis Study Group.
Evaluation of a gastroenteritis severity score for use in outpatient settings.
Pediatrics. 2010;125(6):e1278–85.
12. Schnadower D, Tarr P, Gorelick M, O'Connell K, Roskind C, Powell E, Rao J,
Bhatt S, Freedman S. Validation of the modified Vesikari score in children
with gastroenteritis in 5 US emergency departments. J Pediatric
Gastroenterol Nutr. 2013;57(4):514.
13. Kelly L, Richer L, Ali S, Plint A, Poonai N, Freedman S, Knisley L, Shimmin C,
Hickes S, W’t Jong G, Pechlivanoglou P. Innovative approaches to
investigator-initiated, multicentre paediatric clinical trials in Canada. BMJ
Open. 2019;9(6):e029024.
14. WCHRI, “Women and Children's Health Research Institute, (WCHRI). Data
Coordinating Centre.,” https://www.wchri.org/data-coordinating-centre.,
Accessed August 7, 2018., 2018.
15. Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J. Research
electronic data capture (REDCap) - a metadata-driven methodology and
workflow process for providing translational research informatics support. J
Biomed Inform. 2009;42(2):377–81.
16. Kim A, Chang J, Shin S, Yi H, Moon J, Ko J, Oh S. Epidemiology and factors
related to clinical severity of acute gastroenteritis in hospitalized children after
the introduction of rotavirus vaccination. J Korean Med Sci. 2017;32(3):465–74.
17. Vanderkooi O, Xie J, Lee B, Pang X, Chui L, Payne D, MacDonald J, Ali S,
MacDonald S, Drews S, Osterreicher L. A prospective comparative study of
children with gastroenteritis: emergency department compared with
symptomatic care at home. Eur J Clin Microbiol Infect Dis. 2019;38(12):2371–9.
18. Xie J, Nettel-Aguirre A, Lee B, Chui L, Pang X, Zhuo R, Parsons B, Vanderkooi
O, Tarr P, Ali S, Dickinson J. Relationship between enteric pathogens and
acute gastroenteritis disease severity: a prospective cohort study. Clin
Microbiol Infect. 2019;25(4):454–61.
19. Freedman S, Williamson-Urquhart S, Farion K, Gouin S, Willan A, Poonai N,
Hurley K, Sherman P, Finkelstein Y, Lee B, Pang X. Multicenter trial of a
combination probiotic for children with gastroenteritis. N Engl J Med. 2018;
379(21):2015–26.
20. Bassler D, Briel M, Montori V, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D,
Walter S, Guyatt G, STOPIT-2 Study Group. Stopping randomized trials early
for benefit and estimation of treatment effects: systematic review and meta-
regression analysis. JAMA. 2010;303(12):1180–7.
21. Marschner I, Schou I. Underestimation of treatment effects in sequentially
monitored clinical trials that did not stop early for benefit. Stat Methods
Med Res. 2019;28(10–11):3027–41.
22. SAS Institute Inc. Base SAS 9.4 Procedures Guide. 5th ed. Cary: SAS Institute
Inc.; 2015. Available: http://support.sas.com.
23. R Core Team, R. A language and environment for statistical computing.
Vienna: R Foundation for Statistical Computing; 2018.
24. White I, Royston P, Wood A. Multiple imputation using chained equations:
issues and guidance for practice. Stat Med. 2011;30(4):377–99.
25. Graham J, Olchowski A, Gilreath T. How many imputations are really
needed? Some practical clarifications of multiple imputation theory. Prev
Sci. 2007;8(3):206–13.
26. Carpenter J, Kenward M, White I. Sensitivity analysis after multiple
imputation under missing at random: a weighting approach. Stat Methods
Med Res. 2007;16(3):259–75.
27. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models
using lme4. J Stat Softw. 2015;67(1):1–48.
28. Lee P. Bayesian statistics. London: Arnold Publication; 1997.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Heath et al. Trials          (2020) 21:735 Page 8 of 8
